Gambro Lundia Ab

Gambro Ab

Fresenius Medical Care Deutschland Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Anders Wieslander

Jan P Sternby

Ola Carlsson

Olof Jansson

Lennart Jönsson

Torbjorn Linden

Torbjoern Linden

Thomas Hertz

Gunita Forsbäck

Therese Svensson

Malin Ernebrant

Kristian Solem

Bo Olde

Anders John Wellings

Anders Nilsson

Per Kjellstrand

Torbjörn Linden

Helena Jeppsson

Gabriela Godaly

Sture Hobro

Mattias Holmer

Eddie Nilsson

Reinhold Deppisch

Sven A Jonsson

Edward S Szpara

Lennart Joensson

Petra Åhl

Karin Sandin

Viktoria Hancock

Simon Enarsson

Jan Sternby

Per Ulinder

Eva Svensson

Anna Szilagyi

Theodor Sandstroem

Gunita Forsback

Per-Ola Wictor

Ragnar Tryggvason

Pascal Bernard

Peder Flank

Lars-Fride Olsson

Gert-Inge Bertinsson

Husam Mohammed

Evi Martinson

Torbj&ouml;rn Linden

Theodor Sandström

Ellinor Broms

Anders Andren

Giorgio Cappelli

Thomas Henle

Anne Dawnay

Sten-Börje Lindqvist

Magnus Braide

Tobjoern Linden

Gunita Forsb&auml;ck

Sten-Boerje Lindqvist

Petra Åhl

Jeffrey Cook

Gunita FORSBÄCK

Lennart JÖNSSON

Petra ÅHl

Torbjörn LINDÉN

Giuseppe Sasso

Petra Ahl

Lennart Jonsson

Sarah Lynn Mathiot

Paul Straka

The invention provides a first concentrate comprising lactate and calcium ions, said first concentrate having increased stability against precipitation at temperatures around +4° C., said first concentrate being useful for preparing a ready-to-use dialysis fluid by mixing said first concentrate with water and optionally a second concentrate comprising glucose, wherein that the lactate concentration L(expressed in moles per litre, M) of the concentrate fulfills the conditions: a) L>0.8 M; and b) L<(1.9−0.4×Ca) M; and wherein Cais the calcium concentration of the ready-to-use dialysis fluid expressed in millimoles per litre (mM).

Dialysis concentrate

Methods and systems are provided for preparing a ready-to-use peritoneal dialysis fluid for peritoneal dialysis of a patient having a deficiency in potassium. The methods comprise mixing, immediately before administration to the patient, appropriate amounts of at least a first concentrate, a second concentrate, and a third concentrate with an appropriate amount of water to form a ready-to-use dialysis fluid. The first concentrate comprises glucose, has a pH of between 1.5 and 4, and is free of potassium ions; the second concentrate comprises a physiologically acceptable buffer and is free of potassium ions; and the third concentrate comprises the physiologically acceptable buffer and potassium ions.

Method and system for providing peritoneal dialysis fluids with variable potassium concentrations

A method and a system comprising an integrated water purifying apparatus with a pre-filter circuit including a particle filter and an activated carbon filter arranged to produce pre-treated water; a fluid circuit arranged to receive pre-treated water from the pre-filter circuit, the fluid circuit including an RO-pump and a Reverse Osmosis (RO) device arranged to produce purified water; a heating device arranged to heat purified water from the RO device to a temperature above&#xb0;0 C.; the water purifying apparatus further arranged to heat disinfect the fluid circuit using the heated purified water. The system further comprises a line set connected to the purified water outlet connector at a water line connector of the line set, wherein the line set includes at least one sterile sterilizing grade filter arranged to further filter the purified water.

System and a method for producing microbiologically controlled fluid

The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Dialysis solution, formulated and stored in two parts, comprising phosphate

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention the glucose and the at least one magnesium salt, are present as anhydrous components in the dialysis acid precursor composition.

Dialysis precursor composition product

The present invention concerns an anticoagulation fluid comprising 10-40 mM citrate and 0.1-4 mM phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in a dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit.

Anticoagulation fluid comprising citrate and phosphate

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.

Dialysis precursor composition

The present invention concerns a system for preparing a ready-to-use peritoneal dialysis fluid. The system comprises a) a proportioning device; b) at least one source of water; c) at least one source of first concentrate adapted for connection with a) and b), d) at least one source of second concentrate adapted for connection with a) and b), and optionally, e) at least one source of further concentrate adapted for connection with a) and b), wherein the first concentrate comprises glucose and has a pH of between 1.5 and 4, and wherein the second concentrate comprises a physiologically acceptable buffer and has a pH of between 5.5 and 9.0.

System for proportioning fluids

The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of-mM, is sterile and has a pH of-. The present invention further relates to a method for producing the medical solution and the use thereof.

A peritoneal dialysis system includes a disposable set, source(s) of concentrate(s), a water purifier, a sensor, and a control unit. The disposable set includes a water port, an inlet port, a drain port, a water line in fluid communication with the water port, a drain line in fluid communication with the drain port, and a container to hold a dialysis fluid prepared by mixing water and the concentrate(s). The source(s) of concentrate(s) are in fluid communication with the inlet port, and the water purifier is configured to purify water and feed the water towards the water port so the sensor can detect a fluid property. The control unit is configured to deliver dialysis fluid mixed in the disposable set to the drain line and water purified by the water purifier along the water line, into the disposable set, and out the drain line to push dialysis fluid to the sensor.

Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation including testing thereof

A control system () is arranged to control the operation of an apparatus () for extracorporeal blood treatment. The apparatus () comprises an extracorporeal blood circuit () and a connection system (C) for connecting the blood circuit () to the vascular system of a patient. The blood circuit () comprises a blood processing device (), and at least one pumping device (). The control system is operable to switch between a pre-treatment mode and a blood treatment mode. The blood treatment mode involves operating the blood circuit () to pump blood from the vascular system via the connection system (C) through the blood processing device () and back to the vascular system via the connection system (C). The control system () is operable to obtain measurement data from at least one energy transfer sensor () arranged to sense a transfer of energy between the patient and the connection system (C) or between the patient and the blood circuit (). The control system () is configured to, in the pre-treatment mode, process the measurement data for identification of a characteristic change indicating a connection of the blood circuit () to the vascular system of the patient, and, upon such identification, take dedicated action. The action may involve activating at least part of a patient protection system and/or enabling entry into the blood treatment mode. The control system may be included in an apparatus () for blood treatment, such as a dialysis machine.

Controlling an apparatus for fluid transfer to and/or from a subject

The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 10-40 mM citrate, and 0.1-2.0 mM phosphate; and the at least one treatment fluid comprises 0-5 mM total calcium, 0-8 mM citrate, and 0.1-2.0 mM phosphate; with provisos that the at least one treatment fluid comprises citrate when total calcium concentration is 0 mM; and the at least one treatment fluid comprises calcium when the citrate concentration is 0 mM. The present invention further concerns a system for regional citrate anticoagulation in an extracorporeal blood circuit.

Multipart fluid system and a system for regional citrate anticoagulation with a phosphate comprising anticoagulation fluid

The present invention concerns an anticoagulation fluid comprising 10-40 mM citrate and 0.1-4 mM phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in the dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit.

The present invention concerns a multipart fluid system for dialysis therapy, wherein the multipart fluid system comprises an anticoagulation fluid and at least one treatment fluid from the group consisting of dialysis fluid and infusion fluids. According to the invention the anticoagulation fluid comprises 15-40 mM citrate; and the at least one treatment fluid comprises 1.5-8 mM citrate and &#x2265;10 mM bicarbonate. The present invention further concerns a system for citrate anticoagulation in an extracorporeal blood circuit.

Multipart fluid system and a system for citrate anticoagulation in an extracorporeal blood circuit

Growing community of inventors

Lund, Sweden

Anders Wieslander